Study validates a new risk model that allows for more accurate risk estimates, encourages shared decision-making, and helps ...

Edwards Lifesciences Corporation (NYSE:EW) is one of the best medical technology stocks to invest in. On February 11, Stifel reiterated its Buy rating on Edwards Lifesciences and kept its price target ...

Detailed price information for Edwards Lifesciences Corp (EW-N) from The Globe and Mail including charting and trades.

Edwards Lifesciences reports strong Q4 2025 results with 13.3% sales growth to $1.57B, driven by TAVR and TMTT performance gains.

Edwards Lifesciences Corporation (NYSE:EW) Q4 2025 Earnings Call Transcript February 10, 2026 Edwards Lifesciences ...

Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.

Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter and full-year ended Dec. 31, 2025.

Edwards said it has increased confidence in its 2026 projected adjusted EPS of $2.90 to $3.05 and 2026 full year sales growth rate guidance of 8 to 10%. [Photo courtesy of Edwards Lifesciences] ...

Edwards Lifesciences (EW) grew TAVR sales 12.4% to $1.15B while Boston Scientific (BSX) exited TAVR entirely for cardiovascular diversification. Boston Scientific’s operating income surged 384.5% to ...